New Content  edit
Get The App!

Loading the player...
An Overview of the Phase III RECOURSE Study– TAS-102 (LONSURF® - trifluridine and tipiracil)
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
A discussion with Robert J. Mayer, MD, Dana-Farber Cancer Institute on the subject of the Phase III RECOURSE Study Trial, including discussing patient enrollment, primary outcome and results, survival benefit, subgroup findings, administration and dosing issues, side effects discussion, and many other details surrounding the results of the TAS-102 RECOURSE Study. See the downloadable pdf below for a complete list of questions that was asked of Dr. Mayer.